Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by experts in the field of dermatology and gastroenterology. We are exploring new ways to treat these diseases, including alternatives to topical steroids, which can have serious side-effects. This innovative approach is made possible by proprietary technology developed to inhibit the inflammatory process at its inception rather than after inflammation has occurred. Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. We also intend to expand our pipeline across multiple indications, which could include acne or other inflammatory disorders. For example, EB02 is a formulation developed to treat hemorrhoids. We have also licensed other technology and are in discussions to expand our portfolio with investigational medicines to treat other serious skin and gastrointestinal conditions.
Source
